- Home
- MNPR vs LYEL Comparison
MNPR vs LYEL Comparison
Compare MNPR & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- LYEL
- Stock Information
- Founded
- MNPR 2014
- LYEL 2018
- Country
- MNPR United States
- LYEL United States
- Employees
- MNPR N/A
- LYEL N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- MNPR Health Care
- LYEL Health Care
- Exchange
- MNPR Nasdaq
- LYEL Nasdaq
- Market Cap
- MNPR 209.3M
- LYEL 207.7M
- IPO Year
- MNPR 2019
- LYEL 2021
- Fundamental
- Price
- MNPR $35.17
- LYEL $8.87
- Analyst Decision
- MNPR Strong Buy
- LYEL Sell
- Analyst Count
- MNPR 6
- LYEL 2
- Target Price
- MNPR $59.60
- LYEL $15.00
- AVG Volume (30 Days)
- MNPR 55.8K
- LYEL 332.0K
- Earning Date
- MNPR 08-08-2025
- LYEL 08-06-2025
- Dividend Yield
- MNPR N/A
- LYEL N/A
- EPS Growth
- MNPR N/A
- LYEL N/A
- EPS
- MNPR N/A
- LYEL N/A
- Revenue
- MNPR N/A
- LYEL $65,000.00
- Revenue This Year
- MNPR N/A
- LYEL N/A
- Revenue Next Year
- MNPR N/A
- LYEL N/A
- P/E Ratio
- MNPR N/A
- LYEL N/A
- Revenue Growth
- MNPR N/A
- LYEL N/A
- 52 Week Low
- MNPR $1.72
- LYEL $7.65
- 52 Week High
- MNPR $54.30
- LYEL $38.40
- Technical
- Relative Strength Index (RSI)
- MNPR 51.51
- LYEL 46.43
- Support Level
- MNPR $31.17
- LYEL $8.52
- Resistance Level
- MNPR $35.01
- LYEL $9.80
- Average True Range (ATR)
- MNPR 2.10
- LYEL 1.22
- MACD
- MNPR 0.11
- LYEL -0.17
- Stochastic Oscillator
- MNPR 46.49
- LYEL 8.84
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.